However, additional immunomodulatory mechanism has been demonstrated through decrease of CD38 positive immunosuppressive regulatory cells, following an increase in both the effector T cell population and T cell receptor clonality.18 Immunomodulatory functions of daratumumab are complex and probably have a continuous influence on bone marrow microenviroment where myeloma cells find their niche, supporting the role of continuative daratumumab treatment. This evidence concerns the gene CD38 and plasma cell myeloma.